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A B S T R A C T
Objectives: No prognostic or predictive biomarkers for oral squamous cell carcinoma (OSCC) exist. We aimed to
discover novel proteins, altered in OSCC, to be further investigated as potential biomarkers, and to improve
understanding about pathways involved in OSCC.
Materials and Methods: Proteomic signatures of seven paired healthy and OSCC tissue samples were identified
using ultra-definition quantitative mass spectrometry, then analysed and compared using Anova, principal
component analysis, hierarchical clustering and OPLS-DA modelling. A selection of significant proteins that were
also altered in the serum from a previous study (PMID: 28632724) were validated immunohistochemically on an
independent cohort (n= 66) to confirm immunopositivity and location within tumour tissue. Ingenuity
Pathways Analysis was employed to identify altered pathways.
Results: Of 829 proteins quantified, 257 were significant and 72 were able to classify healthy vs OSCC using
OPLS-DA modelling. We identified 19 proteins not previously known to be upregulated in OSCC, including
prosaposin and alpha-taxilin. KIAA1217 and NDRG1 were upregulated in stage IVa compared with stage I tu-
mours. Altered pathways included calcium signalling, cellular movement, haematological system development
and function, and immune cell trafficking, and involved NF-kB and MAPK networks.
Conclusions: We found a set of proteins reliably separating OSCC tumour from healthy tissue, and multiple
proteins differing between stage I and stage IVa OSCC. These potential biomarkers can be studied and validated
in larger cohorts.
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Introduction
Oral squamous cell carcinoma (OSCC) is the most common type of
head and neck cancer globally with an annual incidence of around 275
000 [1]. It is more prevalent in men, and prevalence is increasing [2].
In particular, tongue cancer incidence has been rising in various parts of
the world in recent years, and especially in patients under 45 [1,3].
Strong risk factors include alcohol and tobacco.
Western 5-year survival rates for oral cavity cancer are around 60%
[3–5]. Five-year disease- specific survival (DSS) of OSCC of the mobile
tongue decreases as the stage increases. In Finland, 5-year DSS is 87%
for stage I carcinomas, but 51% for stage IV. Interestingly, recurrence
occurred in 22–34% of patients, slightly varying by stage [6].
However, the TNM classification does not fully account for OSCC
patients’ outcomes [7]; tumours with the same TNM stage can exhibit
different behaviours, treatment responses, and prognoses [8]. Different
molecules and pathways have been linked with OSCC cancer beha-
viours, such as the VEGF-Flt-1 pathway with invasion [9], kallikrein-
related peptidase with metastatic capacity [10], and glutathione-per-
oxidase-I overexpression with poor prognosis [11]. None of these are
yet in clinical use.
Nano Ultra-Performance Liquid Chromatography Label-Free Ultra-
Definition Mass Spectrometry (nUPLC-UDMSE) is a highly sensitive
form of mass spectrometry (MS), capable of quantifying hundreds-to-
thousands of proteins in solution. nUPLC-UDMSE discovery-driven
analysis offers a unique avenue to discover proteins and pathways that
are previously not known to be altered in OSCC. Previously, studies
using non-pooled paired healthy and OSCC tissue samples for direct
comparison with MS have used a gel-based matrix to register the dif-
ferences between the cases and controls after which protein spots are
identified using MS [12–14]. However, shotgun proteomics, as done
here, and the electrophoresis approaches have different scopes and
limitations. Electrophoresis mainly homes in on critical alterations such
as isoform differences, and post-translational modifications, whereas
shotgun approaches aim for a broad overview of proteomic changes,
including those with smaller abundances, and allows for novel protein
discovery. These two approaches can be complementary [15].
The primary aim of this study was to identify and quantify the
differences between healthy tissue and OSCC using nUPLC-UDMSE
proteomics. In particular, we aimed to discover novel proteins with
significantly different expression in OSCC compared with controls,
along with differences in protein expression between high- and low-
grade tumours. This will facilitate future research to assess whether
these proteins can be used as potential new prognostic or predictive
biomarkers, for example predicting different clinical behaviours of
OSCCs. Additionally, the discovery of proteins involved can help in
identifying important pathways in OSCC pathogenesis and thus po-
tential therapeutic targets.
Materials and methods
Briefly, tissues of primary OSCC of the mobile tongue, and paired
healthy tongue epithelium were taken preoperatively and immediately
frozen. At the time of analysis, the tissues were thawed and lysed, and
protein extraction was performed. The proteins were trypsin digested,
and the tryptic peptide mixture was analysed using mass spectrometry
(nUPLC-UDMSE), to identify proteins differing between OSCC and
paired healthy epithelium. Statistical classification and separation
techniques were performed to ensure clear differences between OSCC
and healthy tissue. Pathway analysis using two methods were per-
formed to assess altered pathways within OSCC to gain greater under-
standing. We additionally performed a comparison between stage I and
stage IVa OSCC. Selected proteins that have previously been found to be
altered in serum of OSCC [16,17] and that we also found to be altered
in the tissue were validated with immunohistochemistry (IHC). A tissue
microarray block of 66 patients with oral tongue OSCC was used for this
IHC analysis. Patient and tumour information is in Supplementary
Table 1. Detailed information about the materials and methods are
found in Supplementary File 1. The workflow can be visualised in
Fig. 1.
Ethical approval was granted by the institutional Research Ethics
Committee at the Helsinki University Hospital (Dnro: 64/13/03/02/
2014). All patients provided informed written consent to participate in
the study.
Results
Proteomics of OSCC and healthy tongue tissue
Of 829 proteins with two or more unique peptides that were
quantified, 257 proteins were statistically significant (Supplementary
Table 2).
The majority of proteins were present in both the cancer and control
tissue in differing amounts, but one protein (alpha-taxilin) was absent
Fig. 1. Overview of methods employed, and results obtained. Mass spectro-
metry using nUPLC-UDMSE (Nano Ultra Performance Liquid Chromatography
Label Free Ultra-definition mass spectrometry was performed on OSCC of the
tongue and paired healthy controls. Anova analysis was performed on these,
with a p-value cut-off of 0.05. For group classification, PCA, OPLS-DA and
Hierarchical Clustering Analysis were used, and significant proteins were
identified using OPLS-DA analysis. Using String PPI and IPA, pathways altered
in OSCC were identified. Furthermore, stage IVa vs stage I OSCC protein ex-
pressions were compared. Validation was performed on selected proteins, to
confirm their presence is consistent in tumour samples, and to identify which
cells within the tumour express these proteins. These proteins are known to be
significantly altered in OSCC serum compared to controls in a previous study
[16]. Key: ANOVA - Analysis of Variance; IHC – immunohistochemistry; IPA -
Ingenuity Pathways Analysis; MS - mass spectrometry; OPLS-DA - Orthogonal
Projections to Latent Structures Discriminant Analysis; PCA - Principal Com-
ponent Analysis; String PPI - Protein-protein Interaction (via String).
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Fig. 2. Separation between the OSCC proteins de-
monstrated with three different methods. Principal
Component Analysis when all the proteins (two or
more unique peptides) were considered is shown in
Panel A. Principal Component Analysis, when using
proteins passing Anova cutoff p-value of 0.05, is
shown in Panel B. Visualisation of OPLS-DA
(Orthogonal Projections to Latent Structures
Discriminant Analysis) modelling by S-plot, gave us
the significantly different proteins, which could
classify the OSCC from healthy tissue, is shown in
Panel C. The upper right quadrant (with positive
values) show proteins upregulated in OSCC tongue
tissue; the lower left quadrant (with negative values)
shows the proteins upregulated in the healthy tongue
tissue. The cut-off used to separate significantly dif-
ferent proteins from other proteins was±0.7. The
blue line represents the cut-off for proteins upregu-
lated in OSCC, the purple line represents the cut-off
for proteins downregulated in OSCC. Hierarchical
clustering, using the Euclidean Similarity Index,
shows branching between the OSCC and paired
healthy tissue based on protein expression (Panel D).
(For interpretation of the references to colour in this
figure legend, the reader is referred to the web ver-
sion of this article.)
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in 5 of the 7 control samples, with low levels in the other two samples.
Other highly upregulated proteins include neutrophil defensin 1
(DEFA1), and sickle tail protein homologue (KIAA1217), with mean
fold changes (FC) of 18.2 and 18, respectively.
For confirmation of the separation and for further filtering of the
proteins differing between the OSCC and healthy control tissue samples,
various supervised and unsupervised statistical analyses were em-
ployed: Principal Component Analysis (PCA); Orthogonal Projections to
Latent Structures Discriminant Analysis (OPLS-DA); Hierarchical
Clustering Analysis (HCA). In all three of these analyses there was a
clear separation between the OSCC and control tissues. HCA showed
separate branches of OSCC and healthy samples based on protein
abundances (Fig. 2d).
PCA was used to determine and visualise the principal axes of
protein abundance variation between the two groups. This showed a
complete separation between cancer and healthy tissue when using all
829 proteins, with the separation becoming even clearer when just the
statistically significant proteins were included (Fig. 2a and b).
OPLS-DA was used to model the differences between the two
groups. One OSCC tissue sample from patient number two was removed
as it lay beyond the 95% confidence range. An S-plot was generated
from the data (Fig. 2c). Proteins exceeding the p(corr) cut-off value
of ± 0.7 were considered to be significant (Table 1). 35 upregulated
and 37 downregulated proteins with FC of 2 or more were found in this
s-plot, such as DEFA1 (FC 19.8; p(corr) 0.84), S100A7 (FC 5.1; p(corr)
0.85), carbonic anhydrase 1 (CA1) (FC 3.3; p(corr) 0.92). of these S-plot
proteins had an area under the receiver operating characteristic curve
(AUROC) of 1.0.
Comparison between proteomic signatures of the stage I and stage IVa OSCC
The proteomic differences between stage I and stage IVa OSCC were
performed using the same methods as for the tumours versus controls.
There were 17 protein differences with Anova p < 0.05, which can be
seen in Table 2. The most upregulated of these being KIAA1217 (FC
4.94) and NDRG1 (FC 4.12). The most downregulated proteins were
cytochrome b-c1 complex (FC -2.64) and heat shock protein HSP 90
alpha (FC -2.61). There was some overlap on PCA when using all the
827 proteins (Fig. 3a), however upon using the statistically significant
proteins, there was a clear separation between stage I and stage IVa
(Fig. 3b).
Immunohistochemistry of carbonic anhydrase 1 (CA1), S100A7, and
neutrophil defensin 1 (DEFA1)
CA1, S100A7 and DEFA1 were proteins, which were also found to
be altered in the serum of OSCC patients [17], as well being some of the
most differentiating tissue proteins after OPLS-DA modelling. IHC of
these proteins was performed on an independent tissue microarray
(TMA) block cohort of OSCCs, and separate healthy tissue samples from
OSCC patients. This confirmed stronger staining in OSCC than healthy
epithelium. S100A7 showed heterogeneous cytoplasmic, membranous
and nuclear positivity in tumour tissue, whereas in the controls posi-
tivity was present in only the epithelial keratin layer. DEFA1 im-
munopositivity was strong in tumour cells, both cytoplasm and nuclei,
and additional positivity was detected in inflammatory cells sur-
rounding the cancer tissue. In the control tissue, positivity was cyto-
plasmic throughout the epithelium, with more intense, and additional
membranous positivity in the basal cell layers. CA1 showed moderate
cytoplasmic positivity throughout the tumour tissue, and also mem-
branous positivity in some tumours. Inflammatory cells also had im-
munopositivity. In the controls, positivity was localised to the epithe-
lium, and was stronger in the basal layer. Fig. 4 shows examples of, and
the proportions of mild, moderate and strong tumour staining positivity
by intensity in the tumour.
Pathway analysis of OSCC tissue
We performed two analytical methods to determine the important
networks and pathways altered in OSCC compared to healthy tissue.
String protein–protein interactions (PPI) shows direct connections
linking the S-plot proteins as shown in Fig. 5, where there are clusters of
cytoskeletal proteins such as myosin and tropomyosin chains, and
clusters of nuclear proteins such as ALYREF (THO complex subunit 4),
NAP1L1 (nucleosome assembly protein 1-like 1), PABPN1 (Poly-
adenylate-binding protein 2), DNAJC8 (dnaJ homolog subfamily C
member 8). Ingenuity pathway analysis (IPA) shows the significantly
altered networks in OSCC, i.e. those enriched in the S-plot proteins. IPA
includes proteins via which these proteins are known to interact, thus
filling in the gaps of the proteins that may not have been detected. The
top networks enriched were 1: ‘Cellular movement, haematological
system development and function, immune cell trafficking’, 2: ‘Her-
editary disorder, organismal injury and abnormalities, skeletal and
muscle disorders, 3: ‘Cell-to-cell signalling and interaction, cellular
movement, nervous system development and function’, 4: ‘Infectious
diseases, dermatological diseases and condition, organismal injury and
abnormalities’. These are all significant and highly enriched networks,
with network scores between 31 and 56, and enriched with 16 to 25
proteins. This method verifies the s-plot proteins’ significance on a
pathway level. The overlay of both network analysis methods further
shows that there is crossover between all of these OSCC networks. For
example, a connection between ALYREF (THO complex subunit 4) and
DNAJC8 connects Networks 2 and 3, connections between stathmin 1
(STMN1) and tropomyosins (connecting Networks 1 and 2).
IPA also identified significant canonical pathways enriched with the
p < 0.05 proteins (Supplementary Fig. 1). The top canonical pathways
include calcium signalling, regulation of actin-based motility by Rho,
actin cytoskeleton signalling and tight junction signalling.
Discussion
OSCC is often detected late with the consequences of poor survival.
Treatment can also be functionally impairing. OSCC incidence is in-
creasing and has a high recurrence rate [6]. The disease course is un-
predictable, without any established biomarkers for prognostication or
prediction. Such biomarkers are needed urgently. Additionally, it is
imperative to uncover the pathobiology of OSCC at the tissue level to
identify potential treatment targets.
Proteomic comparisons
nUPLC-UDMSE discovery-driven analysis offers a unique avenue to
discover proteins and pathways that are previously not known to be
altered in OSCC. Some similar patterns were found, when compared to
previous proteomic studies [12–14] such as proteasome activator,
peripherin, keratin (KRT) 17 and cofilin-1 upregulation [12], down-
regulation of cytoskeletal proteins such as myosin light and heavy
chains, tropomyosins (except upregulation of tropomyosin 4) [14], and
upregulation of matrix-metalloproteinase 9, S100A7, thymosin beta 10,
tenascin C, calreticulin, and downregulation of lumican [18].
The 257 proteins significantly differing between OSCC and healthy
tissue were further modelled using OPLS-DA, which classifies samples
based on their protein signature and shows their separation and simi-
larities in a way that is difficult to obtain using other means. Among the
S-plot proteins generated from this analysis (Table 1), there were 19
proteins, which to our knowledge are not previously known to be up-
regulated in OSCC, although some have been found in other cancers.
These could be further studied as potential biomarkers. Those with the
greatest abundance include prosaposin (PSAP) and Acidic leucine-rich
nuclear phosphoprotein 32 family member B (ANP32B). The rest are
found in Table 1, along with p-value, fold change and AUROC in-
formation. ANP32B, with an AUROC of 0.939, is upregulated in
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Table 1
The significant proteins obtained from an OPLS-DA (Orthogonal Projections to Latent Structures Discriminant Analysis) S-plot with a p(corr) cut-off of +/−0.7, of
OSCC compared to healthy controls, are shown here. Proteins are sorted from the highest to lowest p(corr) values. Table heading explanations: UniProt: UniProt
accession number; Gene name: the gene name, retrieved from UniProt; Protein name: the recommended name of the protein; All peptides: total number of identified
peptides from the protein in our study; Unique peptides: the number of peptides, unique to the protein found, identified in our study; Anova p-value: the p-value
calculated using Anova; AUROC: the area under the receiver operating characteristic curve; AUROC 95% CI: 95% confidence interval of the AUROC value; Fold
change: mean fold change of the protein values, when comparing cancer to healthy tissue; p[1]: S-plot protein loading; p(corr): correlation coefficient. Where there
are multiple uniport accession numbers for a protein, it represents the grouping of proteins, explained in Supplementary File 1 (page 3, line 21). Novel upregulated
proteins in OSCC tissue are shown in bold.
UniProt Gene name Protein name All peptides Unique
peptides






P00915 CA1 Carbonic anhydrase 1 8 8 9.11E-04 1.00 – 3.3 0.01 0.92
Q86U42 PABPN1 Polyadenylate-binding protein 2 5 2 4.99E-04 1.00 – 3.1 0.01 0.89
Q01105;P0DME0 SET Protein SET 24 17 1.72E-03 0.96 0.83–1 1.9 0.03 0.87
P31151 S100A7 Protein S100-A7 31 14 6.58E-03 0.96 0.84–1 5.1 0.05 0.85
A0A0B4J269 N/A Uncharacterized protein 16 2 5.60E-03 1.00 – 3.1 0.00 0.84
P59665;P59666 DEFA1 Neutrophil defensin 1 8 7 1.79E-03 1.00 – 19.8 0.05 0.84
Q96K17 BTF3L4 Transcription factor BTF3 homolog 4 3 2 1.37E-04 0.92 0.74–1 4.6 0.01 0.83
P63313 TMSB10 Thymosin beta-10 5 4 1.07E-02 1.00 – 3.6 0.05 0.83
Q8N6V9 TEX9 Testis-expressed sequence 9 protein 3 2 2.07E-03 0.98 0.90–1 3.9 0.01 0.81
P67809 YBX1 Nuclease-sensitive element-binding
protein 1
8 4 9.35E-03 0.96 0.84–1 4.3 0.02 0.80
Q86SG5 S100A7A Protein S100-A7A 15 2 1.32E-02 0.96 0.84–1 18.3 0.00 0.80
Q15468 STIL SCL-interrupting locus protein 3 3 7.25E-03 0.96 0.84–1 4.8 0.01 0.80
Q9Y2V2 CARHSP1 Calcium-regulated heat-stable protein 1 8 6 3.01E-03 0.94 0.80–1 2.4 0.02 0.79
P27797 CALR Calreticulin 47 38 9.26E-04 0.94 0.76–1 2.4 0.08 0.79
O75937 DNAJC8 DnaJ homolog subfamily C member 8 5 2 2.02E-02 0.88 0.67–1 2.2 0.00 0.78
Q96MG8 PCMTD1 Protein-L-isoaspartate O-
methyltransferase domain-containing
protein 1
3 2 1.45E-02 0.96 0.84–1 1.8 0.02 0.78
P55209 NAP1L1 Nucleosome assembly protein 1-like 1 15 11 1.13E-02 0.94 0.76–1 3.2 0.02 0.77
Q96AG4 LRRC59 Leucine-rich repeat-containing protein 59 3 2 1.10E-02 0.92 0.71–1 3.6 0.01 0.77
A6NDA9 LRIT2 Leucine-rich repeat, immunoglobulin-
like domain and transmembrane
domain-containing protein 2
2 2 3.36E-02 0.86 0.60–1 2.7 0.01 0.76
Q92688 ANP32B Acidic leucine-rich nuclear
phosphoprotein 32 family member B
17 8 4.35E-03 0.94 0.76–1 2.1 0.04 0.76
P67936 TPM4 Tropomyosin alpha-4 chain 63 18 6.36E-04 0.94 0.80–1 2.4 0.07 0.75
P53999 SUB1 Activated RNA polymerase II
transcriptional coactivator p15
5 4 1.45E-02 0.92 0.72–1 3.5 0.01 0.75
P11021 HSPA5 78 kDa glucose-regulated protein 82 61 1.91E-04 0.94 0.76–1 1.9 0.09 0.75
P49321 NASP Nuclear autoantigenic sperm protein 24 21 4.72E-03 0.96 0.83–1 2.1 0.02 0.75
P40222 TXLNA Alpha-taxilin 3 2 1.56E-03 1.00 – 26 0.00 0.74
P80511 S100A12 Protein S100-A12 11 8 1.05E-02 1.00 – 5.1 0.03 0.74
P07602 PSAP Prosaposin 40 30 1.13E-04 0.98 0.88–1 2.5 0.06 0.73
Q9NZZ3 CHMP5 Charged multivesicular body protein 5 3 2 1.55E-02 0.98 0.88–1 5.1 0.01 0.73
P35232 PHB Prohibitin 5 2 3.62E-02 0.94 0.76–1 4 0.00 0.73
Q86V81 ALYREF THO complex subunit 4 9 5 1.56E-03 0.96 0.88–1 2.4 0.02 0.73
O00515;P42766 LAD1 Ladinin-1 31 24 4.61E-03 1.00 – 1.5 0.02 0.73
P16949; Q93045 STMN1 Stathmin 10 5 7.42E-03 0.94 0.76–1 2.1 0.01 0.73
P04003 C4BPA C4b-binding protein alpha chain 5 4 7.82E-03 1.00 – 6.7 0.01 0.72
O43399 TPD52L2 Tumor protein D54 10 5 4.85E-03 0.90 0.71–1 1.7 0.03 0.72
Q04695 KRT17 Keratin, type I cytoskeletal 17 56 20 1.36E-02 0.94 0.80–1 2 0.04 0.72
P29034 S100A2 Protein S100-A2 6 6 1.83E-02 0.86 0.64–1 2 0.03 0.71
Q8WWX9 SELM Selenoprotein M 3 2 7.88E-03 0.90 0.67–1 3.3 0.01 0.71
Q9P0L0 VAPA Vesicle-associated membrane protein-
associated protein A
7 4 5.08E-03 0.90 0.66–1 2.2 0.01 0.71
P30040 ERP29 Endoplasmic reticulum resident protein
29
22 16 4.98E-03 0.94 0.74–1 1.8 0.03 0.70
P54727 RAD23B UV excision repair protein RAD23
homolog B
10 5 1.24E-02 0.94 0.76–1 2.4 0.02 0.70
O14879 IFIT3 Interferon-induced protein with
tetratricopeptide repeats 3
9 5 5.80E-03 0.98 0.88–1 9.2 0.01 0.70
P07585 DCN Decorin 40 31 3.03E-03 1.00 – −4.6 −0.12 −0.70
Q5BKX8 MURC Muscle-related coiled-coil protein 2 2 1.58E-03 1.00 – −36.9 −0.01 −0.71
P02585 TNNC2 Troponin C, skeletal muscle 48 41 1.06E-03 1.00 – −11.5 −0.14 −0.71
P09493 TPM1 Tropomyosin alpha-1 chain 74 26 6.71E-03 1.00 – −5.4 −0.12 −0.72
P13646 KRT13 Keratin, type I cytoskeletal 13 61 31 1.24E-04 1.00 – −6.2 −0.09 −0.72
P51888 PRELP Prolargin 27 24 8.04E-04 1.00 – −5.7 −0.09 −0.72
O75112 LDB3 LIM domain-binding protein 3 17 12 8.01E-03 0.98 0.92–1 −5.3 −0.05 −0.72
P04083 ANXA1 Annexin A1 98 74 5.83E-04 1.00 – −2.8 −0.18 −0.73
P20774 OGN Mimecan 30 26 1.31E-03 1.00 – −5.9 −0.06 −0.73
P05976 MYL1 Myosin light chain 1/3, skeletal muscle
isoform
77 55 6.70E-04 1.00 – −12.3 −0.24 −0.74
Q9UKX2 MYH2 Myosin-2 127 33 1.17E-02 0.94 0.77–1 −2.1 −0.06 −0.74
P00568 AK1 Adenylate kinase isoenzyme 1 27 15 2.16E-03 1.00 – −3.8 −0.06 −0.74
(continued on next page)
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colorectal carcinoma [19] and breast cancer, and knockdown in cancer
cells induced G1 arrest [20]. Alpha-taxilin, with an AUROC of 1, is
interesting through its absence in 5 of the 7 control samples. It has not
been found in OSCC before, but in colorectal cancer its overexpression
correlates with proliferation activity [21], and is associated with me-
tastatic and invasive potential of renal cell carcinoma [22]. These may
be of interest for future research in OSCC.
The two most upregulated proteins in stage IVa tumours, compared
with stage I (Table 2), were KIAA1217 and protein NDRG1, both linked
with proto-oncogenes. Little is known of KIAA1217 in cancer. It was
recently discovered as a novel fusion partner gene with the RET proto-
oncogene in one case of lung adenocarcinoma, whereby the fusion of
RET with KIAA1217 led to activation of downstream signalling mole-
cules: STAT3, AKT, and ERK. This was linked with increased tumour
cell invasion in the study [23]. However, there are no further studies or
reports of this protein in carcinoma progression. Also known as n-myc
downstream-regulator protein 1, NDRG1 is a metastasis suppressor
gene that inhibits the NF-κB (nuclear factor-κB) pathway, thus in-
hibiting functions such as angiogenesis, proliferation, migration and
invasion [24]. Its over-expression in OSCC has been linked in one study
with long-term specific survival [25]. As the n numbers were small in
our study, with three stage I and four stage IVa tumours, more in-
vestigation will be required to validate these results, especially with
regards to the relatively unknown KIAA1217.
Three of the most significantly different proteins in the tissue pro-
teomic analysis found on S-plot, that were also altered in serum OSCC
compared to healthy [16], were S100A7, DEFA1 and CA1.
CA1 has been discovered in other tumours, such as breast cancer
and small cell lung cancer (SCLC). In breast cancer, CA1 blockade with
siRNA in tumour cell lines stimulated apoptosis and cell migration,
suggesting that it may have an important role in mediating these
processes [26]. Its upregulation in SCLC serum compared with benign
lung disease patients, and healthy controls, caused it to be suggested as
a potential biomarker [27]. Carbonic anhydrases are downstream pro-
teins of hypoxia-inducible factor, which becomes stabilised under hy-
poxic conditions, for example in tumour cells, and mediates the tran-
scription of proteins involved in glycolysis, angiogenesis and pH
regulation [28]. Levels of CA1 in our study had a fold change of 3.4 in
the tissue, compared with healthy samples. In the tumour tissue, CA1
immunopositivity was stronger than in controls. It has recently shown a
similar upregulation in OSCC tissue using electrophoresis-based pro-
teomics [14]. Other carbonic anhydrase family members IX and XII
have been extensively investigated in cancers, including CAIX in OSCC
[29]. There are some promising carbonic anhydrase inhibitors; phase 1
trials are currently underway for the selective carbonic anhydrase IX
inhibitor SLC-0111 in patients with advanced solid tumours [30].
DEFA1 is produced by epithelial cells and neutrophils, and has been
identified in multiple carcinomas, including overexpression in human
oral tongue OSCC [31]. Another previous tongue OSCC study, which
showed an association between neutrophil invasion and lymph node
metastasis, higher stage, and increased rate of tumour recurrence, also
demonstrated strong DEFA1 immunopositivity in neutrophils within
tumour tissue but not in the surrounding tissue [32]. That study showed
high protein fold changes in OSCC compared with control, similar to
our fold change of 19.8 found with MS. In our study, IHC demonstrated
DEFA1 immunopositivity in both inflammatory cells and tumour cells.
Mild to moderate positivity was also seen in normal epithelia, however
no particular staining of inflammatory cells in the control samples.
S100 proteins are known to be involved in tumours; some members as
tumour suppressors and others act as tumour promotors [33]. S100A7 is a
key player in tumour migration, invasion and induction of epithelial-me-
senchymal transition, among others in OSCC [34]. In our study, S100A7
Table 1 (continued)
UniProt Gene name Protein name All peptides Unique
peptides






P31415 CASQ1 Calsequestrin-1 23 14 2.94E-04 1.00 – −16.3 −0.07 −0.74
Q9UBG3 CRNN Cornulin 55 46 1.21E-04 1.00 – −5.4 −0.20 −0.75
P07951 TPM2 Tropomyosin beta chain 83 28 9.48E-04 1.00 – −3.9 −0.14 −0.76
P06753 TPM3 Tropomyosin alpha-3 chain 67 25 3.25E-03 0.98 0.88–1 −2.5 −0.08 −0.77
P51884 LUM Lumican 49 35 5.83E-03 1.00 – −3.6 −0.17 −0.77
P48788 TNNI2 Troponin I, fast skeletal muscle 19 11 1.19E-03 1.00 – −5.4 −0.05 −0.77
P02144 MB Myoglobin 71 59 1.31E-04 1.00 – −21.5 −0.25 −0.78
P10916 MYL2 Myosin regulatory light chain 2,
ventricular/cardiac muscle isoform
54 35 3.72E-04 1.00 – −6.7 −0.14 −0.78
Q15847;Q9BZL4 ADIRF Adipogenesis regulatory factor 8 6 1.01E-03 1.00 – −4.9 −0.04 −0.78
Q6NZI2 PTRF Polymerase I and transcript release factor 22 16 1.17E-02 0.96 0.82–1 −2.2 −0.04 −0.78
Q9BUF5 TUBB6 Tubulin beta-6 chain 14 6 2.26E-03 0.94 0.74–1 −5.8 −0.05 −0.79
P08590 MYL3 Myosin light chain 3 39 26 5.86E-04 0.98 0.88–1 −11.6 −0.12 −0.79
P17661 DES Desmin 69 44 8.52E-04 1.00 – −3.3 −0.06 −0.81
Q16610 ECM1 Extracellular matrix protein 1 14 14 1.21E-04 0.98 0.92–1 −3.7 −0.03 −0.81
P40926 MDH2 Malate dehydrogenase, mitochondrial 16 11 2.30E-02 0.92 0.76–1 −1.9 −0.03 −0.81
P30086 PEBP1 Phosphatidylethanolamine-binding
protein 1
22 17 6.30E-04 1.00 – −2.2 −0.06 −0.81
Q9HCY8 S100A14 Protein S100-A14 13 10 1.38E-03 1.00 – −2.9 −0.03 −0.81
Q8N1N4 KRT78 Keratin, type II cytoskeletal 78 11 5 3.91E-03 0.96 0.84–1 −2.8 −0.01 −0.81
Q9NQ38 SPINK5 Serine protease inhibitor Kazal-type 5 57 35 7.72E-05 0.94 0.80–1 −2.4 −0.05 −0.82
P13805 TNNT1 Troponin T, slow skeletal muscle 7 5 1.29E-04 1.00 – −5.8 −0.02 −0.82
P02511 CRYAB Alpha-crystallin B chain 12 9 1.32E-05 1.00 – −9.8 −0.03 −0.83
P14174 MIF Macrophage migration inhibitory factor 10 7 1.85E-03 0.94 0.76–1 −2.2 −0.07 −0.83
P19013;P14136;
Q6KB66
KRT4 Keratin, type II cytoskeletal 4 50 32 5.23E-04 1.00 – −3.3 −0.07 −0.85
P14649 MYL6B Myosin light chain 6B 26 17 5.63E-05 0.98 0.88–1 −4.8 −0.04 −0.86
Q12836 ZP4 Zona pellucida sperm-binding protein 4 2 2 1.52E-02 0.86 0.57–1 −2.6 −0.01 −0.87
O60437;P80217 PPL Periplakin 104 59 1.16E-04 1.00 – −1.9 −0.07 −0.88
O15231 ZNF185 Zinc finger protein 185 20 13 1.36E-04 1.00 – −2.6 −0.03 −0.95
A. Dickinson et al. Oral Oncology 86 (2018) 206–215
211
expression was detected in all tumour samples. Interestingly, there was
heterogeneity in positivity in the tumour tissue, shown in Fig. 4. In head
and neck squamous cell carcinoma (HNSCC), nuclear S100A7 has been
associated with reduced disease-free survival [35]. Members of the S100
protein family are differently expressed in various cancers – expression
patterns depend on the tumour, its subtype and stage [33]. In HNSCC, the
majority of the S100 proteins are downregulated whereas in most other
cancers they tend to be upregulated (33), contrasting with our findings of
Fig. 3. Separation between the stage IVa compared to stage I samples using Principal Component Analysis (PCA). A: PCA of stage I and stage IVa samples, when
expression of all proteins with two or more unique peptides were considered, is shown here. B: PCA when all proteins passing the cut-off of Anova p-value 0.05, is
shown here.
Table 2
Proteomic comparison between OSCC tissue, stage I and stage IVa. Table of significant up- (in bold) and downregulated proteins in stage IVa cancers compared with
those in stage I cancers. The proteins have been sorted according to fold change, which ranges from 1.51–4.94 in the proteins upregulated in stage IVa, and 1.5–2.6 in
the proteins downregulated in stage IVa, compared to stage I OSCC. Heading explanations: UniProt: UniProt accession number; Gene name: the gene name, retrieved
from UniProt; Protein name: the recommended name of the protein; All peptides: total number of identified peptides from the protein in our study; Unique peptides:
the number of peptides, unique to the protein found, identified in our study; Anova p-value: the p-value calculated using Anova; Fold change: mean fold change of the
protein values, when comparing stage IVa to Stage I. Where there are multiple uniport accession numbers for a protein, it represents the grouping of proteins,
explained in Supplementary File 1 (page 3, line 21).
UniProt Gene name Protein name All peptides Unique peptides Anova p-value Fold change
Q5T5P2 KIAA1217 Sickle tail protein homolog 4 2 0.021171 4.938
Q92597 NDRG1 Protein NDRG1 13 12 0.020015 4.124
P23434 GCSH Glycine cleavage system H protein, mitochondrial 8 3 0.047383 1.542
Q01105;P0DME0 SET Protein SET 24 17 0.024139 1.513
P07919;A0A096LP55 UQCRH Cytochrome b-c1 complex subunit 6, mitochondrial 9 9 0.047026 −2.646
Q14568 HSP90AA2P Heat shock protein HSP 90-alpha A2 13 5 0.000494 −2.612
P04259 KRT6B Keratin, type II cytoskeletal 6B 73 2 0.030769 −2.201
Q16610 ECM1 Extracellular matrix protein 1 14 14 0.042774 −2.154
P06702 S100A9 Protein S100-A9 76 65 0.014422 −2.049
O43768;P56211 ENSA Alpha-endosulfine 7 5 0.049813 −1.969
P13284 IFI30 Gamma-interferon-inducible lysosomal thiol reductase 6 4 0.025037 −1.959
Q9Y281 CFL2 Cofilin-2 17 3 0.044786 −1.903
Q9HCY8 S100A14 Protein S100-A14 13 10 0.026441 −1.832
P15311 EZR Ezrin 43 15 0.006186 −1.767
P07951 TPM2 Tropomyosin beta chain 83 28 0.006667 −1.67
Q9H3N1 TMX1 Thioredoxin-related transmembrane protein 1 2 2 0.018378 −1.623
Q96FQ6 S100A16 Protein S100-A16 8 7 0.007353 −1.545
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other S100 proteins S100A2, 7, 7A, 12 being significantly upregulated in
the OSCCs, which could be the particular pattern in tongue cancer. Clinical
trials are ongoing for targeting other S100 proteins, like S100B in mela-
noma [36], confirming that there is a possibility to target these proteins
therapeutically.
Pathway analysis
One aim of our study was to gain insight into the pathways and
networks upregulated in the tongue cancer compared with healthy
tongue tissue from the same patient. The canonical pathways
(Supplementary Fig. 1) involved in OSCC include calcium signalling,
cell-to-cell interaction signalling, and immune system pathways invol-
ving phagocytes, amongst others.
Calcium signalling has a fundamental biological role, evolutionarily
developed to be at the centre of almost all cellular processes, including
signalling between cells, transcription, motility, innate immunity and
apoptosis [37]. In cancer cells the calcium homeostasis is disrupted, as
can be seen as the top canonical pathway involved. It is well established
that calcium signalling alterations are implicated in tumour induction,
angiogenesis, proliferation and metastasis [38]. Other examples of al-
terations are that, calcium-regulated membrane protein mutations,
such as the IP3R (Inositol triphosphate receptor), have been detected in
HNSCC [39], and the PMCA1 (plasma membrane Ca2+ATPase iso-
form 1) calcium transporter expression has been found to be down-
regulated in OSCC [38]. In our samples, a handful of calcium related
proteins were upregulated, including but not limited to calreticulin,
calponin 1 and 3, reticulocalbin, S100 proteins, which were upregu-
lated, and calsequestrin was downregulated.
The network most enriched with the S-plot proteins, suggesting the
most disrupted networks, was ‘Cellular Movement, Haematological
System Development and Function, Immune Cell Trafficking’, linking in
with the calcium signalling and other top canonical pathways. This
network was almost completely enriched in S-plot proteins (Fig. 5). It
centres around NF-κB and MAPK (mitogen activated protein kinase),
and contains multiple groups of proteins such as the S100s and the
keratins amongst others. NF-κB plays a role in the regulation of various
genes, including matrix metalloproteinases, anti-apoptotic factors, ad-
hesion molecules, cytokines [40]. MAPKs are involved in the regulation
of cell differentiation, proliferation and death in OSCC [41].
In addition to their important role in mechanical stability and
structural integrity of epithelial cells, keratins have additional functions
including protection from stress, wound healing and apoptosis [42].
Expression of keratin isoforms differs in various cancers, reflecting tu-
mour activity, and they thus have the potential to serve as prognostic
markers as fragments of the cytokeratins have been demonstrated in the
circulation. The cytokeratin detection tests known as TPA, which
measures cytokeratins 8, 18 and 19 in the serum, and CYFRA-1, which
measures soluble cytokeratin 18 fragments, have been documented in
various epithelial cell related tumours including head and neck cancers
[43], as ways to monitor progression and response to treatment. KRT17
has been suggested as a diagnostic marker for OSCC and is highly
Fig. 4. Immunohistochemistry of S100A7, neutrophil defensin 1, and carbonic anhydrase 1. The top composite image shows immunohistochemical staining patterns
using: anti-defensin 1 antibodies (first row of images); anti-S100A7 antibodies (second row of images); anti-carbonic anhydrase 1 antibodies (third row) in the
tumour samples at 200x magnification. Control images are on the right-hand panel at 100x magnification to show the whole epithelial layer. The images were taken
with a Nicon Eclipse 80i microscope. Below the composite image are the numbers and percentage of tumours with different staining intensities for each antibody,
expressed in a tabular format.
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upregulated in the OSCC tissue on IHC [44]. In one study, KRT17 with
low KRT13 was suggestive of malignant changes within oral lesions
[45], which correlates with our results of downregulated KRT13 (FC
-6.19) and upregulated KRT17 (FC 1.98) in the tumour tissue.
Conclusions
We have shown that based on tissue proteomics, tongue cancer
tissue samples can be separated from samples of healthy adjacent tissue.
With an MS technique, we were able to identify a set of 35 upregulated
and 37 downregulated statistically relevant proteins that most reliably
represent this separation, many of which were novel in OSCC. These
proteins were found to participate in processes including calcium sig-
nalling, epithelial integrity, neutrophil functioning, and cellular
movement. There were some overlapping proteins compared to pre-
vious proteomic analysis however several novel proteins were detected,
such as alpha-taxilin. Additionally, we show that KIAA1217 and
NDRG1 are upregulated in stage IVa OSCC compared with stage I. We
need further research to clarify whether the expression of some of these
key proteins could serve as a potential biological classification com-
ponent of different OSCC tumours.
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